Common Contracts
356 similar Open Market Sale Agreement contracts by AC Immune SA, ACELYRIN, Inc., Achieve Life Sciences, Inc., others
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • November 13th, 2024 • Palladyne AI Corp. • Services-prepackaged software • New York
Palladyne AI Corp., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • November 13th, 2024 • ACELYRIN, Inc. • Pharmaceutical preparations • New York
AMENDED AND RESTATED OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • November 7th, 2024 • Atea Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • November 7th, 2024 • Assembly Biosciences, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • November 7th, 2024 • Virgin Galactic Holdings, Inc • Transportation services • New York
Virgin Galactic Holdings, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $300,000,000 on the terms set forth in this agreement (this “Agreement”).
AMENDED & RESTATED OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • October 31st, 2024 • Travere Therapeutics, Inc. • Pharmaceutical preparations • New York
Travere Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”) on the terms set forth in this amended and restated agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENT1Open Market Sale Agreement • October 31st, 2024 • Kymera Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Kymera Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $300,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • October 25th, 2024 • Tiziana Life Sciences LTD • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • October 15th, 2024 • Aehr Test Systems • Instruments for meas & testing of electricity & elec signals • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • September 27th, 2024 • Achieve Life Sciences, Inc. • In vitro & in vivo diagnostic substances • New York
Achieve Life Sciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Common Shares”), having an aggregate offering price of up to $50,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTOpen Market Sale Agreement • September 20th, 2024 • Eledon Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
AMENDED & RESTATED OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • September 3rd, 2024 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTOpen Market Sale Agreement • August 30th, 2024 • Ardmore Shipping Corp • Deep sea foreign transportation of freight • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • August 23rd, 2024 • Guardant Health, Inc. • Services-medical laboratories • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • August 12th, 2024 • Apogee Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • August 9th, 2024 • Inotiv, Inc. • Services-commercial physical & biological research • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • August 8th, 2024 • HOOKIPA Pharma Inc. • Pharmaceutical preparations • New York
HOOKIPA Pharma Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $50,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • August 6th, 2024 • Corvus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • August 6th, 2024 • AC Immune SA • Pharmaceutical preparations • New York
AC Immune SA, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland, with registered seat in Ecublens (VD), Switzerland (the “Company”), proposes, subject to the conditions stated herein, to sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), the Company’s common shares, nominal value CHF 0.02 per share (the “Common Shares”), having an aggregate offering price of up to $80.0 million on the terms set forth in this agreement (this “Agreement”). Execution of this Agreement will supersede and replace the existing open market sale agreement (the “Existing Agreement”) between the Company and the Agent, dated May 5, 2021, with both parties acknowledging that the Existing Agreement has been terminated as of the date hereof.
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • August 6th, 2024 • ADC Therapeutics SA • Pharmaceutical preparations • New York
ADC Therapeutics SA, a Swiss stock corporation (société anonyme) domiciled in Epalinges, Switzerland, and organized under the laws of Switzerland (the “Company”), proposes, subject to the terms and conditions stated herein, to sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), common shares of the Company, nominal value CHF 0.08 per share (the “Common Shares”), having an aggregate offering price of up to $100,000,000 on the terms set forth in this agreement (this “Agreement”).
AMENDED & RESTATED OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • August 2nd, 2024 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • August 1st, 2024 • Aldeyra Therapeutics, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • July 19th, 2024 • Soleno Therapeutics Inc • Electromedical & electrotherapeutic apparatus • New York
JEFFERIES LLCOpen Market Sale Agreement • July 3rd, 2024 • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • June 20th, 2024 • Tempest Therapeutics, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • June 14th, 2024 • Alvotech • Biological products, (no disgnostic substances) • New York
Alvotech, a public limited liability company (société anonyme) incorporated and existing under the laws of the Grand Duchy of Luxembourg (“Luxembourg”), having its registered office at 9, rue de Bitbourg, L-1273 Luxembourg, and registered with the Luxembourg Register of Commerce and Companies (R.C.S. Luxembourg) under number B258884 (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and/or sell from time to time through Jefferies LLC, as sales agent, subscriber and/or principal (the “Agent”), the Company’s ordinary shares, $0.01 nominal value (valeur nominale) per share (the “Ordinary Shares”) on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • May 17th, 2024 • GameStop Corp. • Retail-computer & computer software stores • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • May 15th, 2024 • Orchestra BioMed Holdings, Inc. • Surgical & medical instruments & apparatus • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • May 15th, 2024 • Mereo BioPharma Group PLC • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • May 8th, 2024 • Avadel Pharmaceuticals PLC • Pharmaceutical preparations • New York
Avadel Pharmaceuticals plc, an Irish incorporated public limited company (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), the Company’s ordinary shares, nominal value $0.01 per share (the “Ordinary Shares”), on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • April 22nd, 2024 • Vivani Medical, Inc. • Electromedical & electrotherapeutic apparatus • New York
Vivani Medical, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $75,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTOpen Market Sale Agreement • March 22nd, 2024 • Adicet Bio, Inc. • Pharmaceutical preparations • New York
Adicet Bio, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • March 5th, 2024 • Praxis Precision Medicines, Inc. • Pharmaceutical preparations • New York
Praxis Precision Medicines, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $150 million on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • March 4th, 2024 • Astria Therapeutics, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENT1Open Market Sale Agreement • February 29th, 2024 • Chimerix Inc • Pharmaceutical preparations • New York
Chimerix, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Common Shares”), having an aggregate offering price of up to $75,000,000 on the terms set forth in this agreement (this “Agreement”).
